Authors : Tanu Priya; Dr. Sanjay Kumar Singh

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/yhj2bxv6

Scribd : https://tinyurl.com/3tzsfuf7

DOI : https://doi.org/10.38124/ijisrt/25jul1698

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder marked by the pathological accumulation of amyloid-β plaques, neurofibrillary tangles due to tau hyperphosphorylation, and a profound imbalance in metal ion homeostasis. Increasing evidence suggests that transition metals such as iron (Fe), copper (Cu), and zinc (Zn) contribute to the pathogenesis of AD by catalyzing the production of reactive oxygen species (ROS) through redox cycling, thus exacerbating oxidative stress and protein misfolding. Chelation of these metals is emerging as a viable therapeutic strategy to mitigate these effects. This study investigates flavonoids extracted from Ginkgo biloba—specifically quercetin, kaempferol, and isorhamnetin—as natural, multifunctional agents capable of chelating redox-active metals and scavenging free radicals. Using a comprehensive biochemical approach, we examined their molecular structures, binding mechanisms, and pharmacological efficacy through spectrophotometric assays, antioxidant capacity analyses, and molecular docking simulations. Our findings reveal that these flavonoids exhibit significant Fe(II) and Cu(II) chelation ability, inhibit amyloid aggregation, and demonstrate potent antioxidant activity. Quercetin, in particular, displayed the highest metal binding affinity and radical scavenging potential. By modulating metal ion levels and preventing oxidative damage, Ginkgo biloba- derived flavonoids represent promising neuroprotective candidates in AD treatment. This article offers mechanistic insights into their biochemical behavior, emphasizing their relevance in the development of multi-targeted interventions for Alzheimer’s disease.

References :

1. World Health Organization. (2022). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia
2. Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer’s disease. New England Journal of Medicine, 362(4), 329–344.
3. Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608.
4. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998). Copper, iron and zinc in Alzheimer’s disease senile plaques. Journal of the Neurological Sciences, 158(1), 47–52.
5. Jomova, K., & Valko, M. (2011). Advances in metal-induced oxidative stress and human disease. Toxicology, 283(2–3), 65–87.
6. Smith, M. A., Harris, P. L., Sayre, L. M., & Perry, G. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proceedings of the National Academy of Sciences, 94(18), 9866–9868.
7. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., & Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience, 5(11), 863–873.
8. Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R., ... & Bush, A. I. (2002). Metalloenzyme-like activity of Alzheimer’s disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol, and ascorbate. Journal of Biological Chemistry, 277(43), 40302–40308.
9. Bush, A. I., Pettingell, W. H., Paradis, M. D., & Tanzi, R. E. (2003). Modulation of Aβ adhesion to glycosaminoglycans by Zn2+ and Cu2+. Journal of Biological Chemistry, 278(19), 17401–17407.
10. Atrián-Blasco, E., Conte-Daban, A., & Hureau, C. (2018). Dynamic interactions of metal ions with amyloid peptides involved in neurodegenerative diseases. Coordination Chemistry Reviews, 375, 38–55.
11. Perron, N. R., & Brumaghim, J. L. (2009). A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochemistry and Biophysics, 53(2), 75–100.
12. Oken, B. S., Storzbach, D. M., & Kaye, J. A. (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer’s disease. Archives of Neurology, 55(11), 1409–1415.
13. Weinreb, O., Mandel, S., Amit, T., & Youdim, M. B. (2004). Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. Journal of Nutritional Biochemistry, 15(9), 506–516.
14. Bastianetto, S., Zheng, W. H., & Quirion, R. (2000). Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. British Journal of Pharmacology, 131(4), 711–720.
15. Prajapati, N. D., Purohit, S. S., Sharma, A. K., & Kumar, T. (2011). A Handbook of Medicinal Plants: A Complete Source Book. Agrobios.
16. Iravani, S., & Zolfaghari, B. (2011). Pharmaceutical and nutraceutical effects of quercetin: A bioactive flavonoid. Pharmacognosy Reviews, 5(9), 19.
17. Kaur, R., Arora, S., & Singh, B. (2020). Flavonoids as potential therapeutic agents for neurological disorders. Phytochemistry Reviews, 19, 459–477.
18. Yao, Y., Sang, W., Zhou, M., & Ren, G. (2010). Antioxidant and α-glucosidase inhibitory activity of colored grains in China. Journal of Agricultural and Food Chemistry, 58(2), 770–774.
19. Williams, R. J., Spencer, J. P., & Rice-Evans, C. (2004). Flavonoids: Antioxidants or signalling molecules? Free Radical Biology and Medicine, 36(7), 838–849.
20. He, X., Wang, J., Li, M., Hao, D., Yang, Y., Zhang, C., ... & Li, Y. (2017). Traditional uses, botany, phytochemistry, pharmacology and toxicology of Ginkgo biloba L.: A review. Journal of Ethnopharmacology, 210, 152–190.
21. Dajas, F. (2012). Life or death: Neuroprotective and anticancer effects of quercetin. Journal of Ethnopharmacology, 143(2), 383–396.
22. Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biology, 14, 450–464.
23. Morroni, F., Sita, G., Tarozzi, A., Rimondini, R., Hrelia, P., & Hrelia, S. (2018). Neuroprotective effect of sulforaphane in Alzheimer’s disease. Oxidative Medicine and Cellular Longevity, 2018, 3281783.
24. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
25. Sastre, J., Pallardó, F. V., & Viña, J. (2003). The role of mitochondrial oxidative stress in aging and Alzheimer disease. Current Medicinal Chemistry, 10(24), 2485–2501.
26. Butterfield, D. A., & Boyd-Kimball, D. (2018). Oxidative stress, amyloid-β peptide, and Alzheimer disease: How fish oil supplementation protects brain function. Free Radical Biology and Medicine, 112, 515–525.